SCHEMBL4993440

SCHEMBL4993440

Cc1ccc(C(=O)N2CCc3c(ncnc3NC(=O)CC34CC5CC(CC(C5)C3)C4)C2)cc1

nearest known ligand 0.45

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ABCB11 O95342 1/20 0.45
P2RX7 Q99572 6/20 0.42
GPR55 Q9Y2T6 1/20 0.41
TSHR P16473 1/20 0.41
ALDH1A1 P00352 1/20 0.39
ALOX12 P18054 1/20 0.39
GAA P10253 1/20 0.39
CYP2C19 P33261 1/20 0.39
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4983014 0.91 TSHR (0.42) ABCB11P2RX7GPR55TSHRALDH1A1
SCHEMBL4983774 0.91 P2RX7 (0.49) ABCB11P2RX7GPR55TSHRALDH1A1
SCHEMBL4982846 0.91 GRM5 (0.41) ABCB11P2RX7GPR55TSHRALDH1A1
SCHEMBL4986247 0.91 P2RX7 (0.47) ABCB11P2RX7TSHRALDH1A1ALOX12
SCHEMBL4988553 0.91 SMN1; SMN2 (0.43) ABCB11P2RX7GPR55TSHRALDH1A1
SCHEMBL4985176 0.91 GPR55 (0.42) ABCB11P2RX7GPR55TSHRALDH1A1
SCHEMBL4988881 0.91 P2RX7 (0.49) ABCB11P2RX7GPR55TSHRALDH1A1
SCHEMBL4985309 0.90 ABCB11 (0.44) ABCB11P2RX7TSHRALDH1A1ALOX12
SCHEMBL4989394 0.90 P2RX7 (0.44) ABCB11P2RX7GPR55TSHRALDH1A1
SCHEMBL4986178 0.89 GPR55 (0.40) ABCB11P2RX7GPR55TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080039478-A1 Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof RENOVIS, INC. 2008-02-14 US claimed
EP-1860942-A2 BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF Renovis, Inc. (US) 2007-12-05 EP claimed
US-7297700-B2 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof RENOVIS, INC. (US) 2007-11-20 US claimed
WO-2006102610-A2 BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF RENOVIS, INC. (US) 2006-09-28 WO claimed
US-20060217448-A1 e.g. 4-benzyl-N-[2-(2-chlorophenyl)ethyl]-4,7,9-triazabicyclo[4.4.0]deca-7,9,11-triene-10-carboxamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction RENOVIS, INC. 2006-09-28 US claimed
US-20080039478-A1 Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof RENOVIS, INC. 2008-02-14 US disclosed
US-20080039478-A1 Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof RENOVIS, INC. 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217448-A1 e.g. 4-benzyl-N-[2-(2-chlorophenyl)ethyl]-4,7,9-triazabicyclo[4.4.0]deca-7,9,11-triene-10-carboxamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction PARK7, UACA, PTGER4 ABCB11 4125/4885P2RX7 1619/4885GPR55 292/4885
US-20080039478-A1 Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof P2RX7, P2RX3, P2RX2 ABCB11 933/4885P2RX7 1/4885GPR55 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.